[Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
Gan To Kagaku Ryoho
; 36(12): 2207-9, 2009 Nov.
Article
em Ja
| MEDLINE
| ID: mdl-20037372
ABSTRACT
We examined efficacy and safety of bevacizumab (BV)+modified FOLFOX6 (mFOLFOX6) regimen for unresectable colorectal cancer. We had 16 patients liver metastases 8, lung metastases 4, local recurrences 2, and lymph node metastases 2, as for evaluable lesions. The response rate was 46.6%, and disease control rate was 86.6%. Hepatic metastatectomy was done in two cases after PR response. There was 1 infusion related reaction case, 1 tumor bleeding and 1 anal fistula as the adverse events. In conclusion, the BV+mFOLFOX6 is one of the effective and feasible regimens for unresectable colorectal cancer.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Protocolos de Quimioterapia Combinada Antineoplásica
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Ano de publicação:
2009
Tipo de documento:
Article